Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. PR Newswire
SOPH - SOPHiA GENETICS S.A.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.50
DETAILS
HIGH:
$8.00
LOW:
$7.00
MEDIAN:
$7.50
CONSENSUS:
$7.50
UPSIDE:
53.69%
Stock News
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call Transcript
SOPHiA GENETICS Reports First Quarter 2026 Results
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year period IFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year "We started 2026 strong, delivering 22% year-over-year revenue growth and a record 108,000 genomic analyses on SOPHiA DDMTM," said Jurgi Camblong, PhD.
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually.
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Valuation and Earnings This table compares
SOPHiA GENETICS Q4 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ: SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company's fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and progress in both its clinical and biopharma businesses. 2025 performance and platform scale Co-founder and CEO Dr. Jurgi Camblong described 2025 as
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year Full Year 2025 Financial Results Revenue was $77.3 million, up 19% year-over-year Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year "We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS.
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET.
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory.
Comparing SOPHiA GENETICS (NASDAQ:SOPH) & Precipio (NASDAQ:PRPO)
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Institutional and Insider Ownership 10.5% of Precipio shares
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Risk and Volatility SOPHiA GENETICS has a beta
1,409,160 Shares in SOPHiA GENETICS SA $SOPH Bought by Alta Wealth Advisors LLC
Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS SA (NASDAQ: SOPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,409,160 shares of the company's stock, valued at approximately $6,708,000. SOPHiA GENETICS accounts for about 2.4% of
Price Targets
Sophia Genetics price target raised to $8 from $7 at BTIG
$8.00
(was $4.96)
BTIG
BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH)
$7.00
(was $4.10)
Mark Massaro
·
BTIG
Sophia Genetics price target raised to $7 from $6 at Guggenheim
$7.00
(was $5.35)
Guggenheim
Sophia Genetics price target lowered to $5 from $6 at BTIG
$5.00
(was $3.11)
BTIG
Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley
$5.00
(was $3.92)
Tejas Savant
·
Morgan Stanley
Guggenheim Starts Sophia Genetics SA (SOPH) at Buy
$6.00
(was $4.51)
Subbu Nambi
·
Guggenheim
Sophia Genetics initiated with a Buy at BTIG
$6.00
(was $2.06)
Mark Massaro
·
BTIG